Familial hypercholesterolaemia
KEYWORDS: people, diagnosis, quality, statement, data, treatment, testing, clinical, children, specialist, hypercholesterolaemia, familial hypercholesterolaemia, clinical diagnosis, familial, source

Familial hypercholesterolaemia (FH) FH relates to heterozygous FH only. Adults with FH Adults (aged 16 and older) should have a diagnosis of FH made by a specialist with expertise in FH. Baseline LDL-C The concentration before treatment. Lipid-modifying drug treatment Lipid-modifying drug treatment should be given in accordance with the following: • to achieve the recommended reduction: － offer a high-intensity statin with the lowest acquisition cost as the initial treatment － increase dose of statin to maximum licensed or tolerated dose • ezetimibe monotherapy is recommended if the person is intolerant to statin therapy or there are contraindications to initial statin therapy • co-administer ezetimibe with initial statin therapy when serum total or LDL-C concentration is not appropriately controlled and a change from initial statin therapy to an alternative statin is being considered. Statins are classified as high intensity if they produce greater LDL-C reductions than simvastatin 40 mg (for example, simvastatin 80 mg and appropriate doses of atorvastatin and rosuvastatin). Treatment for FH is usually provided by either a specialist with expertise in FH or a GP through a shared care arrangement. [Adapted from NICE's guideline on familial hypercholesterolaemia, recommendations 1.3.1.2 to 1.3.1.6, 1.3.1.11, and terms used in
